nodes	percent_of_prediction	percent_of_DWPC	metapath
Bosutinib—MERTK—multiple sclerosis	0.394	1	CbGaD
Bosutinib—BTK—Mitoxantrone—multiple sclerosis	0.183	0.768	CbGbCtD
Bosutinib—ABCB1—Methylprednisolone—multiple sclerosis	0.00683	0.0286	CbGbCtD
Bosutinib—CYP3A4—Fingolimod—multiple sclerosis	0.00635	0.0266	CbGbCtD
Bosutinib—ABCB1—Mitoxantrone—multiple sclerosis	0.00498	0.0209	CbGbCtD
Bosutinib—ABCB1—Betamethasone—multiple sclerosis	0.00444	0.0186	CbGbCtD
Bosutinib—ABCB1—Prednisolone—multiple sclerosis	0.00438	0.0184	CbGbCtD
Bosutinib—ABCB1—Prednisone—multiple sclerosis	0.00414	0.0173	CbGbCtD
Bosutinib—CYP3A4—Methylprednisolone—multiple sclerosis	0.00409	0.0171	CbGbCtD
Bosutinib—CYP3A4—Triamcinolone—multiple sclerosis	0.0031	0.013	CbGbCtD
Bosutinib—CYP3A4—Mitoxantrone—multiple sclerosis	0.00298	0.0125	CbGbCtD
Bosutinib—CYP3A4—Betamethasone—multiple sclerosis	0.00266	0.0111	CbGbCtD
Bosutinib—CYP3A4—Prednisolone—multiple sclerosis	0.00262	0.011	CbGbCtD
Bosutinib—ABCB1—Dexamethasone—multiple sclerosis	0.00258	0.0108	CbGbCtD
Bosutinib—CYP3A4—Prednisone—multiple sclerosis	0.00248	0.0104	CbGbCtD
Bosutinib—ABCB1—Methotrexate—multiple sclerosis	0.00208	0.0087	CbGbCtD
Bosutinib—CYP3A4—Dexamethasone—multiple sclerosis	0.00155	0.00648	CbGbCtD
Bosutinib—CAMK2G—Azacitidine—Cladribine—multiple sclerosis	0.000467	0.182	CbGdCrCtD
Bosutinib—EPHB2—Diflorasone—Methylprednisolone—multiple sclerosis	0.000205	0.0796	CbGdCrCtD
Bosutinib—EPHB2—Diflorasone—Betamethasone—multiple sclerosis	0.000201	0.0783	CbGdCrCtD
Bosutinib—EPHB2—Diflorasone—Dexamethasone—multiple sclerosis	0.000201	0.0783	CbGdCrCtD
Bosutinib—EPHB2—Diflorasone—Triamcinolone—multiple sclerosis	0.000197	0.0765	CbGdCrCtD
Bosutinib—EPHB2—Diflorasone—Prednisone—multiple sclerosis	0.000187	0.0726	CbGdCrCtD
Bosutinib—STK25—brain—multiple sclerosis	0.000182	0.00174	CbGeAlD
Bosutinib—EPHB2—Diflorasone—Prednisolone—multiple sclerosis	0.000182	0.0709	CbGdCrCtD
Bosutinib—PTK2—midbrain—multiple sclerosis	0.000182	0.00173	CbGeAlD
Bosutinib—TBK1—midbrain—multiple sclerosis	0.000182	0.00173	CbGeAlD
Bosutinib—EPHB4—medulla oblongata—multiple sclerosis	0.000181	0.00172	CbGeAlD
Bosutinib—EPHA3—brain—multiple sclerosis	0.000181	0.00172	CbGeAlD
Bosutinib—BMPR2—central nervous system—multiple sclerosis	0.000181	0.00172	CbGeAlD
Bosutinib—MAP4K4—nervous system—multiple sclerosis	0.000181	0.00172	CbGeAlD
Bosutinib—BCR—nervous system—multiple sclerosis	0.00018	0.00171	CbGeAlD
Bosutinib—MAP3K7—spinal cord—multiple sclerosis	0.00018	0.00171	CbGeAlD
Bosutinib—STK36—central nervous system—multiple sclerosis	0.000179	0.00171	CbGeAlD
Bosutinib—EPHB3—central nervous system—multiple sclerosis	0.000179	0.00171	CbGeAlD
Bosutinib—IRAK1—midbrain—multiple sclerosis	0.000178	0.0017	CbGeAlD
Bosutinib—MAP3K12—nervous system—multiple sclerosis	0.000178	0.0017	CbGeAlD
Bosutinib—PTK2—spinal cord—multiple sclerosis	0.000177	0.00169	CbGeAlD
Bosutinib—TBK1—spinal cord—multiple sclerosis	0.000177	0.00169	CbGeAlD
Bosutinib—MERTK—central nervous system—multiple sclerosis	0.000177	0.00169	CbGeAlD
Bosutinib—FYN—medulla oblongata—multiple sclerosis	0.000177	0.00169	CbGeAlD
Bosutinib—PLK2—brain—multiple sclerosis	0.000177	0.00169	CbGeAlD
Bosutinib—BMPR2—cerebellum—multiple sclerosis	0.000177	0.00168	CbGeAlD
Bosutinib—SIK3—brain—multiple sclerosis	0.000176	0.00168	CbGeAlD
Bosutinib—STK36—cerebellum—multiple sclerosis	0.000175	0.00167	CbGeAlD
Bosutinib—EPHB3—cerebellum—multiple sclerosis	0.000175	0.00167	CbGeAlD
Bosutinib—RPS6KB1—midbrain—multiple sclerosis	0.000175	0.00166	CbGeAlD
Bosutinib—MAP2K1—nervous system—multiple sclerosis	0.000175	0.00166	CbGeAlD
Bosutinib—STK35—nervous system—multiple sclerosis	0.000175	0.00166	CbGeAlD
Bosutinib—MAP4K4—central nervous system—multiple sclerosis	0.000174	0.00166	CbGeAlD
Bosutinib—CSK—nervous system—multiple sclerosis	0.000174	0.00165	CbGeAlD
Bosutinib—MERTK—cerebellum—multiple sclerosis	0.000173	0.00165	CbGeAlD
Bosutinib—MAP4K5—medulla oblongata—multiple sclerosis	0.000173	0.00165	CbGeAlD
Bosutinib—MAP3K3—medulla oblongata—multiple sclerosis	0.000173	0.00165	CbGeAlD
Bosutinib—AXL—midbrain—multiple sclerosis	0.000173	0.00165	CbGeAlD
Bosutinib—BCR—central nervous system—multiple sclerosis	0.000173	0.00165	CbGeAlD
Bosutinib—CSNK1A1—nervous system—multiple sclerosis	0.000172	0.00164	CbGeAlD
Bosutinib—MAP3K12—central nervous system—multiple sclerosis	0.000172	0.00163	CbGeAlD
Bosutinib—HCK—nervous system—multiple sclerosis	0.000171	0.00163	CbGeAlD
Bosutinib—CLK1—nervous system—multiple sclerosis	0.000171	0.00163	CbGeAlD
Bosutinib—RPS6KB1—spinal cord—multiple sclerosis	0.000171	0.00162	CbGeAlD
Bosutinib—MAP4K4—cerebellum—multiple sclerosis	0.00017	0.00162	CbGeAlD
Bosutinib—STK4—brain—multiple sclerosis	0.00017	0.00161	CbGeAlD
Bosutinib—AXL—spinal cord—multiple sclerosis	0.000169	0.00161	CbGeAlD
Bosutinib—NUAK2—cerebellum—multiple sclerosis	0.000169	0.00161	CbGeAlD
Bosutinib—BCR—cerebellum—multiple sclerosis	0.000169	0.00161	CbGeAlD
Bosutinib—MAP2K1—central nervous system—multiple sclerosis	0.000168	0.0016	CbGeAlD
Bosutinib—STK35—central nervous system—multiple sclerosis	0.000168	0.0016	CbGeAlD
Bosutinib—BMP2K—nervous system—multiple sclerosis	0.000168	0.0016	CbGeAlD
Bosutinib—CAMK2G—nervous system—multiple sclerosis	0.000168	0.0016	CbGeAlD
Bosutinib—MAP3K12—cerebellum—multiple sclerosis	0.000168	0.0016	CbGeAlD
Bosutinib—CAMK1D—brain—multiple sclerosis	0.000168	0.00159	CbGeAlD
Bosutinib—CSK—central nervous system—multiple sclerosis	0.000167	0.00159	CbGeAlD
Bosutinib—SLK—midbrain—multiple sclerosis	0.000167	0.00159	CbGeAlD
Bosutinib—LRRK2—nervous system—multiple sclerosis	0.000167	0.00159	CbGeAlD
Bosutinib—CSNK1A1—central nervous system—multiple sclerosis	0.000166	0.00158	CbGeAlD
Bosutinib—STK24—brain—multiple sclerosis	0.000166	0.00158	CbGeAlD
Bosutinib—EPHB4—midbrain—multiple sclerosis	0.000166	0.00158	CbGeAlD
Bosutinib—CLK1—central nervous system—multiple sclerosis	0.000165	0.00157	CbGeAlD
Bosutinib—HCK—central nervous system—multiple sclerosis	0.000165	0.00157	CbGeAlD
Bosutinib—STK35—cerebellum—multiple sclerosis	0.000164	0.00156	CbGeAlD
Bosutinib—MAP2K1—cerebellum—multiple sclerosis	0.000164	0.00156	CbGeAlD
Bosutinib—CSK—cerebellum—multiple sclerosis	0.000163	0.00155	CbGeAlD
Bosutinib—SLK—spinal cord—multiple sclerosis	0.000163	0.00155	CbGeAlD
Bosutinib—PTK2B—nervous system—multiple sclerosis	0.000162	0.00155	CbGeAlD
Bosutinib—CSNK1A1—cerebellum—multiple sclerosis	0.000162	0.00154	CbGeAlD
Bosutinib—FYN—midbrain—multiple sclerosis	0.000162	0.00154	CbGeAlD
Bosutinib—CAMK2G—central nervous system—multiple sclerosis	0.000162	0.00154	CbGeAlD
Bosutinib—BMP2K—central nervous system—multiple sclerosis	0.000162	0.00154	CbGeAlD
Bosutinib—EPHB4—spinal cord—multiple sclerosis	0.000162	0.00154	CbGeAlD
Bosutinib—CLK1—cerebellum—multiple sclerosis	0.000161	0.00153	CbGeAlD
Bosutinib—LRRK2—central nervous system—multiple sclerosis	0.00016	0.00153	CbGeAlD
Bosutinib—FER—brain—multiple sclerosis	0.00016	0.00153	CbGeAlD
Bosutinib—EPHA5—brain—multiple sclerosis	0.00016	0.00153	CbGeAlD
Bosutinib—TYRO3—brain—multiple sclerosis	0.00016	0.00153	CbGeAlD
Bosutinib—ALK—brain—multiple sclerosis	0.00016	0.00153	CbGeAlD
Bosutinib—ABL2—cerebellum—multiple sclerosis	0.00016	0.00152	CbGeAlD
Bosutinib—YES1—medulla oblongata—multiple sclerosis	0.00016	0.00152	CbGeAlD
Bosutinib—CSNK1E—nervous system—multiple sclerosis	0.00016	0.00152	CbGeAlD
Bosutinib—LYN—brain—multiple sclerosis	0.000159	0.00152	CbGeAlD
Bosutinib—MAP4K5—midbrain—multiple sclerosis	0.000158	0.00151	CbGeAlD
Bosutinib—MAP3K3—midbrain—multiple sclerosis	0.000158	0.00151	CbGeAlD
Bosutinib—BMP2K—cerebellum—multiple sclerosis	0.000158	0.00151	CbGeAlD
Bosutinib—CAMK2G—cerebellum—multiple sclerosis	0.000158	0.00151	CbGeAlD
Bosutinib—FYN—spinal cord—multiple sclerosis	0.000158	0.00151	CbGeAlD
Bosutinib—TAOK3—medulla oblongata—multiple sclerosis	0.000158	0.0015	CbGeAlD
Bosutinib—IRAK4—nervous system—multiple sclerosis	0.000157	0.0015	CbGeAlD
Bosutinib—SIK1—nervous system—multiple sclerosis	0.000157	0.0015	CbGeAlD
Bosutinib—MAP4K1—brain—multiple sclerosis	0.000157	0.00149	CbGeAlD
Bosutinib—MAP3K19—brain—multiple sclerosis	0.000157	0.00149	CbGeAlD
Bosutinib—LRRK2—cerebellum—multiple sclerosis	0.000157	0.00149	CbGeAlD
Bosutinib—ABL1—brainstem—multiple sclerosis	0.000157	0.00149	CbGeAlD
Bosutinib—EGFR—cerebellum—multiple sclerosis	0.000156	0.00149	CbGeAlD
Bosutinib—PTK2B—central nervous system—multiple sclerosis	0.000156	0.00149	CbGeAlD
Bosutinib—BTK—brain—multiple sclerosis	0.000156	0.00149	CbGeAlD
Bosutinib—EPHA4—nervous system—multiple sclerosis	0.000156	0.00148	CbGeAlD
Bosutinib—MAP4K5—spinal cord—multiple sclerosis	0.000155	0.00147	CbGeAlD
Bosutinib—MAP3K3—spinal cord—multiple sclerosis	0.000155	0.00147	CbGeAlD
Bosutinib—ERBB3—nervous system—multiple sclerosis	0.000154	0.00147	CbGeAlD
Bosutinib—TNK2—brain—multiple sclerosis	0.000154	0.00147	CbGeAlD
Bosutinib—CSNK1E—central nervous system—multiple sclerosis	0.000154	0.00146	CbGeAlD
Bosutinib—MAP2K2—nervous system—multiple sclerosis	0.000154	0.00146	CbGeAlD
Bosutinib—ULK3—nervous system—multiple sclerosis	0.000154	0.00146	CbGeAlD
Bosutinib—PTK2B—cerebellum—multiple sclerosis	0.000153	0.00145	CbGeAlD
Bosutinib—MAP3K2—nervous system—multiple sclerosis	0.000153	0.00145	CbGeAlD
Bosutinib—MAP4K2—brain—multiple sclerosis	0.000152	0.00144	CbGeAlD
Bosutinib—SIK1—central nervous system—multiple sclerosis	0.000151	0.00144	CbGeAlD
Bosutinib—IRAK4—central nervous system—multiple sclerosis	0.000151	0.00144	CbGeAlD
Bosutinib—ABL1—retina—multiple sclerosis	0.000151	0.00144	CbGeAlD
Bosutinib—CSNK1E—cerebellum—multiple sclerosis	0.00015	0.00143	CbGeAlD
Bosutinib—EPHA4—central nervous system—multiple sclerosis	0.00015	0.00143	CbGeAlD
Bosutinib—ERBB4—brain—multiple sclerosis	0.00015	0.00143	CbGeAlD
Bosutinib—STK3—brain—multiple sclerosis	0.00015	0.00143	CbGeAlD
Bosutinib—TBK1—nervous system—multiple sclerosis	0.00015	0.00142	CbGeAlD
Bosutinib—PTK2—nervous system—multiple sclerosis	0.00015	0.00142	CbGeAlD
Bosutinib—ERBB3—central nervous system—multiple sclerosis	0.000148	0.00141	CbGeAlD
Bosutinib—MAP2K2—central nervous system—multiple sclerosis	0.000148	0.00141	CbGeAlD
Bosutinib—ULK3—central nervous system—multiple sclerosis	0.000148	0.00141	CbGeAlD
Bosutinib—SIK1—cerebellum—multiple sclerosis	0.000148	0.00141	CbGeAlD
Bosutinib—IRAK4—cerebellum—multiple sclerosis	0.000148	0.00141	CbGeAlD
Bosutinib—ROCK1—brain—multiple sclerosis	0.000148	0.00141	CbGeAlD
Bosutinib—MAP3K2—central nervous system—multiple sclerosis	0.000147	0.0014	CbGeAlD
Bosutinib—EPHA4—cerebellum—multiple sclerosis	0.000147	0.00139	CbGeAlD
Bosutinib—YES1—midbrain—multiple sclerosis	0.000146	0.00139	CbGeAlD
Bosutinib—ERBB3—cerebellum—multiple sclerosis	0.000145	0.00138	CbGeAlD
Bosutinib—ULK3—cerebellum—multiple sclerosis	0.000145	0.00138	CbGeAlD
Bosutinib—MAP2K2—cerebellum—multiple sclerosis	0.000145	0.00138	CbGeAlD
Bosutinib—TAOK3—midbrain—multiple sclerosis	0.000144	0.00137	CbGeAlD
Bosutinib—PTK2—central nervous system—multiple sclerosis	0.000144	0.00137	CbGeAlD
Bosutinib—TBK1—central nervous system—multiple sclerosis	0.000144	0.00137	CbGeAlD
Bosutinib—RPS6KB1—nervous system—multiple sclerosis	0.000144	0.00137	CbGeAlD
Bosutinib—MAP3K2—cerebellum—multiple sclerosis	0.000144	0.00137	CbGeAlD
Bosutinib—BMPR2—brain—multiple sclerosis	0.000144	0.00137	CbGeAlD
Bosutinib—FGR—nervous system—multiple sclerosis	0.000143	0.00136	CbGeAlD
Bosutinib—YES1—spinal cord—multiple sclerosis	0.000143	0.00136	CbGeAlD
Bosutinib—STK36—brain—multiple sclerosis	0.000142	0.00136	CbGeAlD
Bosutinib—EPHB3—brain—multiple sclerosis	0.000142	0.00136	CbGeAlD
Bosutinib—AXL—nervous system—multiple sclerosis	0.000142	0.00135	CbGeAlD
Bosutinib—MAP3K7—cerebellum—multiple sclerosis	0.000142	0.00135	CbGeAlD
Bosutinib—MAP2K5—medulla oblongata—multiple sclerosis	0.000142	0.00135	CbGeAlD
Bosutinib—TAOK3—spinal cord—multiple sclerosis	0.000141	0.00134	CbGeAlD
Bosutinib—MERTK—brain—multiple sclerosis	0.000141	0.00134	CbGeAlD
Bosutinib—TBK1—cerebellum—multiple sclerosis	0.000141	0.00134	CbGeAlD
Bosutinib—PTK2—cerebellum—multiple sclerosis	0.000141	0.00134	CbGeAlD
Bosutinib—RPS6KB1—central nervous system—multiple sclerosis	0.000139	0.00132	CbGeAlD
Bosutinib—CSF1R—medulla oblongata—multiple sclerosis	0.000138	0.00132	CbGeAlD
Bosutinib—MAP4K4—brain—multiple sclerosis	0.000138	0.00132	CbGeAlD
Bosutinib—IRAK1—cerebellum—multiple sclerosis	0.000138	0.00131	CbGeAlD
Bosutinib—FGR—central nervous system—multiple sclerosis	0.000138	0.00131	CbGeAlD
Bosutinib—SRC—spinal cord—multiple sclerosis	0.000137	0.00131	CbGeAlD
Bosutinib—BCR—brain—multiple sclerosis	0.000137	0.00131	CbGeAlD
Bosutinib—NUAK2—brain—multiple sclerosis	0.000137	0.00131	CbGeAlD
Bosutinib—AXL—central nervous system—multiple sclerosis	0.000137	0.0013	CbGeAlD
Bosutinib—MAP3K12—brain—multiple sclerosis	0.000136	0.0013	CbGeAlD
Bosutinib—RPS6KB1—cerebellum—multiple sclerosis	0.000135	0.00129	CbGeAlD
Bosutinib—Gastrointestinal pain—Azathioprine—multiple sclerosis	0.000135	0.00156	CcSEcCtD
Bosutinib—Dizziness—Cladribine—multiple sclerosis	0.000134	0.00155	CcSEcCtD
Bosutinib—AXL—cerebellum—multiple sclerosis	0.000134	0.00128	CbGeAlD
Bosutinib—MAP2K1—brain—multiple sclerosis	0.000134	0.00127	CbGeAlD
Bosutinib—STK35—brain—multiple sclerosis	0.000134	0.00127	CbGeAlD
Bosutinib—EPHA2—nervous system—multiple sclerosis	0.000134	0.00127	CbGeAlD
Bosutinib—Anaphylactic shock—Mitoxantrone—multiple sclerosis	0.000133	0.00154	CcSEcCtD
Bosutinib—Oedema—Mitoxantrone—multiple sclerosis	0.000133	0.00154	CcSEcCtD
Bosutinib—FYN—nervous system—multiple sclerosis	0.000133	0.00127	CbGeAlD
Bosutinib—CSK—brain—multiple sclerosis	0.000133	0.00126	CbGeAlD
Bosutinib—Infection—Mitoxantrone—multiple sclerosis	0.000132	0.00153	CcSEcCtD
Bosutinib—CSNK1A1—brain—multiple sclerosis	0.000132	0.00125	CbGeAlD
Bosutinib—Cardiac disorder—Methylprednisolone—multiple sclerosis	0.000131	0.00152	CcSEcCtD
Bosutinib—CLK1—brain—multiple sclerosis	0.000131	0.00125	CbGeAlD
Bosutinib—HCK—brain—multiple sclerosis	0.000131	0.00125	CbGeAlD
Bosutinib—Neutropenia—Prednisone—multiple sclerosis	0.000131	0.00151	CcSEcCtD
Bosutinib—Thrombocytopenia—Mitoxantrone—multiple sclerosis	0.000131	0.00151	CcSEcCtD
Bosutinib—Body temperature increased—Azathioprine—multiple sclerosis	0.00013	0.00151	CcSEcCtD
Bosutinib—Abdominal pain—Azathioprine—multiple sclerosis	0.00013	0.00151	CcSEcCtD
Bosutinib—MAP4K5—nervous system—multiple sclerosis	0.00013	0.00124	CbGeAlD
Bosutinib—MAP3K3—nervous system—multiple sclerosis	0.00013	0.00124	CbGeAlD
Bosutinib—ABL2—brain—multiple sclerosis	0.00013	0.00124	CbGeAlD
Bosutinib—MAP2K5—midbrain—multiple sclerosis	0.000129	0.00123	CbGeAlD
Bosutinib—Skin disorder—Mitoxantrone—multiple sclerosis	0.000129	0.0015	CcSEcCtD
Bosutinib—SLK—cerebellum—multiple sclerosis	0.000129	0.00123	CbGeAlD
Bosutinib—Vomiting—Cladribine—multiple sclerosis	0.000129	0.00149	CcSEcCtD
Bosutinib—EPHA2—central nervous system—multiple sclerosis	0.000129	0.00122	CbGeAlD
Bosutinib—BMP2K—brain—multiple sclerosis	0.000129	0.00122	CbGeAlD
Bosutinib—CAMK2G—brain—multiple sclerosis	0.000129	0.00122	CbGeAlD
Bosutinib—FYN—central nervous system—multiple sclerosis	0.000128	0.00122	CbGeAlD
Bosutinib—EPHB4—cerebellum—multiple sclerosis	0.000128	0.00122	CbGeAlD
Bosutinib—Rash—Cladribine—multiple sclerosis	0.000128	0.00148	CcSEcCtD
Bosutinib—Dermatitis—Cladribine—multiple sclerosis	0.000128	0.00148	CcSEcCtD
Bosutinib—Immune system disorder—Methylprednisolone—multiple sclerosis	0.000128	0.00148	CcSEcCtD
Bosutinib—LRRK2—brain—multiple sclerosis	0.000127	0.00121	CbGeAlD
Bosutinib—Mediastinal disorder—Methylprednisolone—multiple sclerosis	0.000127	0.00148	CcSEcCtD
Bosutinib—Headache—Cladribine—multiple sclerosis	0.000127	0.00147	CcSEcCtD
Bosutinib—EGFR—brain—multiple sclerosis	0.000127	0.00121	CbGeAlD
Bosutinib—CSF1R—midbrain—multiple sclerosis	0.000126	0.0012	CbGeAlD
Bosutinib—MAP2K5—spinal cord—multiple sclerosis	0.000126	0.0012	CbGeAlD
Bosutinib—FYN—cerebellum—multiple sclerosis	0.000125	0.00119	CbGeAlD
Bosutinib—MAP4K5—central nervous system—multiple sclerosis	0.000125	0.00119	CbGeAlD
Bosutinib—MAP3K3—central nervous system—multiple sclerosis	0.000125	0.00119	CbGeAlD
Bosutinib—Ill-defined disorder—Prednisolone—multiple sclerosis	0.000124	0.00144	CcSEcCtD
Bosutinib—PTK2B—brain—multiple sclerosis	0.000124	0.00118	CbGeAlD
Bosutinib—CSF1R—spinal cord—multiple sclerosis	0.000123	0.00117	CbGeAlD
Bosutinib—Malnutrition—Methylprednisolone—multiple sclerosis	0.000123	0.00142	CcSEcCtD
Bosutinib—PDGFRB—medulla oblongata—multiple sclerosis	0.000123	0.00117	CbGeAlD
Bosutinib—MAP4K5—cerebellum—multiple sclerosis	0.000123	0.00117	CbGeAlD
Bosutinib—MAP3K3—cerebellum—multiple sclerosis	0.000123	0.00117	CbGeAlD
Bosutinib—CSNK1E—brain—multiple sclerosis	0.000122	0.00116	CbGeAlD
Bosutinib—Musculoskeletal discomfort—Mitoxantrone—multiple sclerosis	0.000121	0.00141	CcSEcCtD
Bosutinib—Malaise—Prednisolone—multiple sclerosis	0.000121	0.0014	CcSEcCtD
Bosutinib—Dysgeusia—Triamcinolone—multiple sclerosis	0.000121	0.0014	CcSEcCtD
Bosutinib—Nausea—Cladribine—multiple sclerosis	0.00012	0.0014	CcSEcCtD
Bosutinib—YES1—nervous system—multiple sclerosis	0.00012	0.00114	CbGeAlD
Bosutinib—SIK1—brain—multiple sclerosis	0.00012	0.00114	CbGeAlD
Bosutinib—IRAK4—brain—multiple sclerosis	0.00012	0.00114	CbGeAlD
Bosutinib—STK10—nervous system—multiple sclerosis	0.000119	0.00113	CbGeAlD
Bosutinib—Back pain—Triamcinolone—multiple sclerosis	0.000119	0.00138	CcSEcCtD
Bosutinib—EPHA4—brain—multiple sclerosis	0.000119	0.00113	CbGeAlD
Bosutinib—Dyspnoea—Mitoxantrone—multiple sclerosis	0.000119	0.00138	CcSEcCtD
Bosutinib—TAOK3—nervous system—multiple sclerosis	0.000119	0.00113	CbGeAlD
Bosutinib—ERBB3—brain—multiple sclerosis	0.000118	0.00112	CbGeAlD
Bosutinib—MAP2K2—brain—multiple sclerosis	0.000118	0.00112	CbGeAlD
Bosutinib—ULK3—brain—multiple sclerosis	0.000118	0.00112	CbGeAlD
Bosutinib—MAP3K2—brain—multiple sclerosis	0.000117	0.00111	CbGeAlD
Bosutinib—Decreased appetite—Mitoxantrone—multiple sclerosis	0.000116	0.00134	CcSEcCtD
Bosutinib—YES1—central nervous system—multiple sclerosis	0.000116	0.0011	CbGeAlD
Bosutinib—SRC—nervous system—multiple sclerosis	0.000116	0.0011	CbGeAlD
Bosutinib—MAP3K7—brain—multiple sclerosis	0.000116	0.0011	CbGeAlD
Bosutinib—Fatigue—Mitoxantrone—multiple sclerosis	0.000115	0.00133	CcSEcCtD
Bosutinib—STK10—central nervous system—multiple sclerosis	0.000115	0.00109	CbGeAlD
Bosutinib—TAOK3—central nervous system—multiple sclerosis	0.000114	0.00109	CbGeAlD
Bosutinib—Ill-defined disorder—Triamcinolone—multiple sclerosis	0.000114	0.00133	CcSEcCtD
Bosutinib—TBK1—brain—multiple sclerosis	0.000114	0.00109	CbGeAlD
Bosutinib—PTK2—brain—multiple sclerosis	0.000114	0.00109	CbGeAlD
Bosutinib—Ill-defined disorder—Methylprednisolone—multiple sclerosis	0.000114	0.00132	CcSEcCtD
Bosutinib—Pain—Mitoxantrone—multiple sclerosis	0.000114	0.00132	CcSEcCtD
Bosutinib—YES1—cerebellum—multiple sclerosis	0.000113	0.00108	CbGeAlD
Bosutinib—Diarrhoea—Azathioprine—multiple sclerosis	0.000113	0.00131	CcSEcCtD
Bosutinib—Discomfort—Prednisolone—multiple sclerosis	0.000113	0.00131	CcSEcCtD
Bosutinib—STK10—cerebellum—multiple sclerosis	0.000112	0.00107	CbGeAlD
Bosutinib—PDGFRB—midbrain—multiple sclerosis	0.000112	0.00107	CbGeAlD
Bosutinib—IRAK1—brain—multiple sclerosis	0.000112	0.00107	CbGeAlD
Bosutinib—Abdominal discomfort—Methotrexate—multiple sclerosis	0.000112	0.0013	CcSEcCtD
Bosutinib—TAOK3—cerebellum—multiple sclerosis	0.000112	0.00106	CbGeAlD
Bosutinib—SRC—central nervous system—multiple sclerosis	0.000111	0.00106	CbGeAlD
Bosutinib—Malaise—Triamcinolone—multiple sclerosis	0.000111	0.00129	CcSEcCtD
Bosutinib—Pancytopenia—Methotrexate—multiple sclerosis	0.000111	0.00129	CcSEcCtD
Bosutinib—Malaise—Methylprednisolone—multiple sclerosis	0.000111	0.00129	CcSEcCtD
Bosutinib—RPS6KB1—brain—multiple sclerosis	0.00011	0.00105	CbGeAlD
Bosutinib—Connective tissue disorder—Prednisone—multiple sclerosis	0.00011	0.00127	CcSEcCtD
Bosutinib—Feeling abnormal—Mitoxantrone—multiple sclerosis	0.00011	0.00127	CcSEcCtD
Bosutinib—Oedema—Prednisolone—multiple sclerosis	0.000109	0.00127	CcSEcCtD
Bosutinib—Anaphylactic shock—Prednisolone—multiple sclerosis	0.000109	0.00127	CcSEcCtD
Bosutinib—PDGFRB—spinal cord—multiple sclerosis	0.000109	0.00104	CbGeAlD
Bosutinib—ABL1—medulla oblongata—multiple sclerosis	0.000109	0.00104	CbGeAlD
Bosutinib—FGR—brain—multiple sclerosis	0.000109	0.00104	CbGeAlD
Bosutinib—Neutropenia—Methotrexate—multiple sclerosis	0.000109	0.00127	CcSEcCtD
Bosutinib—Dizziness—Azathioprine—multiple sclerosis	0.000109	0.00126	CcSEcCtD
Bosutinib—Gastrointestinal pain—Mitoxantrone—multiple sclerosis	0.000109	0.00126	CcSEcCtD
Bosutinib—SRC—cerebellum—multiple sclerosis	0.000109	0.00104	CbGeAlD
Bosutinib—AXL—brain—multiple sclerosis	0.000109	0.00104	CbGeAlD
Bosutinib—Upper respiratory tract infection—Methotrexate—multiple sclerosis	0.000109	0.00126	CcSEcCtD
Bosutinib—Cough—Triamcinolone—multiple sclerosis	0.000108	0.00125	CcSEcCtD
Bosutinib—MAP2K5—nervous system—multiple sclerosis	0.000106	0.00101	CbGeAlD
Bosutinib—PKMYT1—Danazol—Prednisone—multiple sclerosis	0.000106	0.0412	CbGdCrCtD
Bosutinib—Urticaria—Mitoxantrone—multiple sclerosis	0.000106	0.00123	CcSEcCtD
Bosutinib—Abdominal pain—Mitoxantrone—multiple sclerosis	0.000105	0.00122	CcSEcCtD
Bosutinib—Body temperature increased—Mitoxantrone—multiple sclerosis	0.000105	0.00122	CcSEcCtD
Bosutinib—Myalgia—Triamcinolone—multiple sclerosis	0.000105	0.00122	CcSEcCtD
Bosutinib—Vomiting—Azathioprine—multiple sclerosis	0.000105	0.00122	CcSEcCtD
Bosutinib—SLK—brain—multiple sclerosis	0.000105	0.000997	CbGeAlD
Bosutinib—Pneumonia—Methotrexate—multiple sclerosis	0.000105	0.00121	CcSEcCtD
Bosutinib—Arthralgia—Methylprednisolone—multiple sclerosis	0.000105	0.00121	CcSEcCtD
Bosutinib—Myalgia—Methylprednisolone—multiple sclerosis	0.000105	0.00121	CcSEcCtD
Bosutinib—Infestation NOS—Methotrexate—multiple sclerosis	0.000104	0.00121	CcSEcCtD
Bosutinib—Infestation—Methotrexate—multiple sclerosis	0.000104	0.00121	CcSEcCtD
Bosutinib—EPHB4—brain—multiple sclerosis	0.000104	0.00099	CbGeAlD
Bosutinib—Rash—Azathioprine—multiple sclerosis	0.000104	0.0012	CcSEcCtD
Bosutinib—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—multiple sclerosis	0.000104	0.0012	CcSEcCtD
Bosutinib—CSF1R—nervous system—multiple sclerosis	0.000104	0.000988	CbGeAlD
Bosutinib—Dermatitis—Azathioprine—multiple sclerosis	0.000104	0.0012	CcSEcCtD
Bosutinib—Ill-defined disorder—Dexamethasone—multiple sclerosis	0.000104	0.0012	CcSEcCtD
Bosutinib—Ill-defined disorder—Betamethasone—multiple sclerosis	0.000104	0.0012	CcSEcCtD
Bosutinib—Discomfort—Triamcinolone—multiple sclerosis	0.000104	0.0012	CcSEcCtD
Bosutinib—Discomfort—Methylprednisolone—multiple sclerosis	0.000103	0.0012	CcSEcCtD
Bosutinib—Headache—Azathioprine—multiple sclerosis	0.000103	0.0012	CcSEcCtD
Bosutinib—MAP2K5—central nervous system—multiple sclerosis	0.000102	0.000975	CbGeAlD
Bosutinib—Renal failure—Methotrexate—multiple sclerosis	0.000102	0.00119	CcSEcCtD
Bosutinib—EPHA2—brain—multiple sclerosis	0.000102	0.000971	CbGeAlD
Bosutinib—FYN—brain—multiple sclerosis	0.000102	0.000969	CbGeAlD
Bosutinib—CSNK1E—Danazol—Prednisone—multiple sclerosis	0.000101	0.0393	CbGdCrCtD
Bosutinib—Immune system disorder—Prednisone—multiple sclerosis	0.000101	0.00117	CcSEcCtD
Bosutinib—Malaise—Betamethasone—multiple sclerosis	0.000101	0.00117	CcSEcCtD
Bosutinib—Malaise—Dexamethasone—multiple sclerosis	0.000101	0.00117	CcSEcCtD
Bosutinib—Anaphylactic shock—Triamcinolone—multiple sclerosis	0.000101	0.00117	CcSEcCtD
Bosutinib—Oedema—Triamcinolone—multiple sclerosis	0.000101	0.00117	CcSEcCtD
Bosutinib—Anaphylactic shock—Methylprednisolone—multiple sclerosis	0.0001	0.00116	CcSEcCtD
Bosutinib—MAP2K5—cerebellum—multiple sclerosis	0.0001	0.000953	CbGeAlD
Bosutinib—CSF1R—central nervous system—multiple sclerosis	0.0001	0.000952	CbGeAlD
Bosutinib—Infection—Triamcinolone—multiple sclerosis	9.99e-05	0.00116	CcSEcCtD
Bosutinib—ABL1—midbrain—multiple sclerosis	9.99e-05	0.00095	CbGeAlD
Bosutinib—Infection—Methylprednisolone—multiple sclerosis	9.97e-05	0.00116	CcSEcCtD
Bosutinib—MAP4K5—brain—multiple sclerosis	9.96e-05	0.000947	CbGeAlD
Bosutinib—MAP3K3—brain—multiple sclerosis	9.96e-05	0.000947	CbGeAlD
Bosutinib—Hepatobiliary disease—Methotrexate—multiple sclerosis	9.85e-05	0.00114	CcSEcCtD
Bosutinib—Nervous system disorder—Methylprednisolone—multiple sclerosis	9.84e-05	0.00114	CcSEcCtD
Bosutinib—Nausea—Azathioprine—multiple sclerosis	9.79e-05	0.00114	CcSEcCtD
Bosutinib—CSF1R—cerebellum—multiple sclerosis	9.78e-05	0.00093	CbGeAlD
Bosutinib—ABL1—spinal cord—multiple sclerosis	9.75e-05	0.000927	CbGeAlD
Bosutinib—Skin disorder—Methylprednisolone—multiple sclerosis	9.75e-05	0.00113	CcSEcCtD
Bosutinib—Malnutrition—Prednisone—multiple sclerosis	9.74e-05	0.00113	CcSEcCtD
Bosutinib—Agranulocytosis—Methotrexate—multiple sclerosis	9.72e-05	0.00113	CcSEcCtD
Bosutinib—Asthenia—Mitoxantrone—multiple sclerosis	9.56e-05	0.00111	CcSEcCtD
Bosutinib—Myalgia—Betamethasone—multiple sclerosis	9.52e-05	0.0011	CcSEcCtD
Bosutinib—Myalgia—Dexamethasone—multiple sclerosis	9.52e-05	0.0011	CcSEcCtD
Bosutinib—Discomfort—Dexamethasone—multiple sclerosis	9.4e-05	0.00109	CcSEcCtD
Bosutinib—Discomfort—Betamethasone—multiple sclerosis	9.4e-05	0.00109	CcSEcCtD
Bosutinib—Pain—Prednisolone—multiple sclerosis	9.35e-05	0.00108	CcSEcCtD
Bosutinib—Hepatitis—Methotrexate—multiple sclerosis	9.35e-05	0.00108	CcSEcCtD
Bosutinib—Urinary tract disorder—Methotrexate—multiple sclerosis	9.23e-05	0.00107	CcSEcCtD
Bosutinib—PDGFRB—nervous system—multiple sclerosis	9.21e-05	0.000877	CbGeAlD
Bosutinib—YES1—brain—multiple sclerosis	9.19e-05	0.000875	CbGeAlD
Bosutinib—Urethral disorder—Methotrexate—multiple sclerosis	9.16e-05	0.00106	CcSEcCtD
Bosutinib—Musculoskeletal discomfort—Triamcinolone—multiple sclerosis	9.16e-05	0.00106	CcSEcCtD
Bosutinib—Musculoskeletal discomfort—Methylprednisolone—multiple sclerosis	9.14e-05	0.00106	CcSEcCtD
Bosutinib—Anaphylactic shock—Betamethasone—multiple sclerosis	9.12e-05	0.00106	CcSEcCtD
Bosutinib—Anaphylactic shock—Dexamethasone—multiple sclerosis	9.12e-05	0.00106	CcSEcCtD
Bosutinib—Oedema—Dexamethasone—multiple sclerosis	9.12e-05	0.00106	CcSEcCtD
Bosutinib—Oedema—Betamethasone—multiple sclerosis	9.12e-05	0.00106	CcSEcCtD
Bosutinib—Diarrhoea—Mitoxantrone—multiple sclerosis	9.12e-05	0.00106	CcSEcCtD
Bosutinib—STK10—brain—multiple sclerosis	9.11e-05	0.000867	CbGeAlD
Bosutinib—TAOK3—brain—multiple sclerosis	9.08e-05	0.000864	CbGeAlD
Bosutinib—Infection—Betamethasone—multiple sclerosis	9.06e-05	0.00105	CcSEcCtD
Bosutinib—Infection—Dexamethasone—multiple sclerosis	9.06e-05	0.00105	CcSEcCtD
Bosutinib—Ill-defined disorder—Prednisone—multiple sclerosis	9.03e-05	0.00105	CcSEcCtD
Bosutinib—Feeling abnormal—Prednisolone—multiple sclerosis	9.01e-05	0.00104	CcSEcCtD
Bosutinib—Anaemia—Prednisone—multiple sclerosis	9e-05	0.00104	CcSEcCtD
Bosutinib—Dyspnoea—Triamcinolone—multiple sclerosis	8.97e-05	0.00104	CcSEcCtD
Bosutinib—Nervous system disorder—Dexamethasone—multiple sclerosis	8.95e-05	0.00104	CcSEcCtD
Bosutinib—Nervous system disorder—Betamethasone—multiple sclerosis	8.95e-05	0.00104	CcSEcCtD
Bosutinib—Thrombocytopenia—Dexamethasone—multiple sclerosis	8.93e-05	0.00104	CcSEcCtD
Bosutinib—Thrombocytopenia—Betamethasone—multiple sclerosis	8.93e-05	0.00104	CcSEcCtD
Bosutinib—PDGFRB—central nervous system—multiple sclerosis	8.87e-05	0.000844	CbGeAlD
Bosutinib—SRC—brain—multiple sclerosis	8.85e-05	0.000842	CbGeAlD
Bosutinib—Erythema multiforme—Methotrexate—multiple sclerosis	8.84e-05	0.00102	CcSEcCtD
Bosutinib—Malaise—Prednisone—multiple sclerosis	8.78e-05	0.00102	CcSEcCtD
Bosutinib—Tinnitus—Methotrexate—multiple sclerosis	8.72e-05	0.00101	CcSEcCtD
Bosutinib—Urticaria—Prednisolone—multiple sclerosis	8.69e-05	0.00101	CcSEcCtD
Bosutinib—Cardiac disorder—Methotrexate—multiple sclerosis	8.68e-05	0.00101	CcSEcCtD
Bosutinib—PDGFRB—cerebellum—multiple sclerosis	8.67e-05	0.000825	CbGeAlD
Bosutinib—Fatigue—Triamcinolone—multiple sclerosis	8.67e-05	0.001	CcSEcCtD
Bosutinib—Fatigue—Methylprednisolone—multiple sclerosis	8.65e-05	0.001	CcSEcCtD
Bosutinib—Pain—Triamcinolone—multiple sclerosis	8.6e-05	0.000997	CcSEcCtD
Bosutinib—Vomiting—Mitoxantrone—multiple sclerosis	8.47e-05	0.000982	CcSEcCtD
Bosutinib—Immune system disorder—Methotrexate—multiple sclerosis	8.44e-05	0.000979	CcSEcCtD
Bosutinib—Mediastinal disorder—Methotrexate—multiple sclerosis	8.42e-05	0.000976	CcSEcCtD
Bosutinib—Rash—Mitoxantrone—multiple sclerosis	8.4e-05	0.000974	CcSEcCtD
Bosutinib—Dermatitis—Mitoxantrone—multiple sclerosis	8.4e-05	0.000973	CcSEcCtD
Bosutinib—Headache—Mitoxantrone—multiple sclerosis	8.35e-05	0.000968	CcSEcCtD
Bosutinib—Musculoskeletal discomfort—Betamethasone—multiple sclerosis	8.31e-05	0.000964	CcSEcCtD
Bosutinib—Musculoskeletal discomfort—Dexamethasone—multiple sclerosis	8.31e-05	0.000964	CcSEcCtD
Bosutinib—Myalgia—Prednisone—multiple sclerosis	8.29e-05	0.000961	CcSEcCtD
Bosutinib—Arthralgia—Prednisone—multiple sclerosis	8.29e-05	0.000961	CcSEcCtD
Bosutinib—Feeling abnormal—Triamcinolone—multiple sclerosis	8.29e-05	0.00096	CcSEcCtD
Bosutinib—Feeling abnormal—Methylprednisolone—multiple sclerosis	8.27e-05	0.000958	CcSEcCtD
Bosutinib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—multiple sclerosis	8.23e-05	0.000954	CcSEcCtD
Bosutinib—ABL1—nervous system—multiple sclerosis	8.21e-05	0.000781	CbGeAlD
Bosutinib—Gastrointestinal pain—Methylprednisolone—multiple sclerosis	8.2e-05	0.000951	CcSEcCtD
Bosutinib—Discomfort—Prednisone—multiple sclerosis	8.19e-05	0.000949	CcSEcCtD
Bosutinib—Malnutrition—Methotrexate—multiple sclerosis	8.14e-05	0.000943	CcSEcCtD
Bosutinib—MAP2K5—brain—multiple sclerosis	8.14e-05	0.000774	CbGeAlD
Bosutinib—Vandetanib—ALB—multiple sclerosis	8.1e-05	0.513	CrCbGaD
Bosutinib—Urticaria—Triamcinolone—multiple sclerosis	7.99e-05	0.000926	CcSEcCtD
Bosutinib—Urticaria—Methylprednisolone—multiple sclerosis	7.97e-05	0.000924	CcSEcCtD
Bosutinib—Dysgeusia—Methotrexate—multiple sclerosis	7.97e-05	0.000924	CcSEcCtD
Bosutinib—Body temperature increased—Triamcinolone—multiple sclerosis	7.95e-05	0.000921	CcSEcCtD
Bosutinib—Anaphylactic shock—Prednisone—multiple sclerosis	7.95e-05	0.000921	CcSEcCtD
Bosutinib—Oedema—Prednisone—multiple sclerosis	7.95e-05	0.000921	CcSEcCtD
Bosutinib—CSF1R—brain—multiple sclerosis	7.94e-05	0.000756	CbGeAlD
Bosutinib—Abdominal pain—Methylprednisolone—multiple sclerosis	7.93e-05	0.000919	CcSEcCtD
Bosutinib—Decreased appetite—Dexamethasone—multiple sclerosis	7.93e-05	0.000919	CcSEcCtD
Bosutinib—Decreased appetite—Betamethasone—multiple sclerosis	7.93e-05	0.000919	CcSEcCtD
Bosutinib—Nausea—Mitoxantrone—multiple sclerosis	7.92e-05	0.000918	CcSEcCtD
Bosutinib—ABL1—central nervous system—multiple sclerosis	7.91e-05	0.000752	CbGeAlD
Bosutinib—Infection—Prednisone—multiple sclerosis	7.89e-05	0.000915	CcSEcCtD
Bosutinib—Gastrointestinal disorder—Betamethasone—multiple sclerosis	7.88e-05	0.000913	CcSEcCtD
Bosutinib—Gastrointestinal disorder—Dexamethasone—multiple sclerosis	7.88e-05	0.000913	CcSEcCtD
Bosutinib—Back pain—Methotrexate—multiple sclerosis	7.87e-05	0.000912	CcSEcCtD
Bosutinib—Fatigue—Betamethasone—multiple sclerosis	7.87e-05	0.000912	CcSEcCtD
Bosutinib—Fatigue—Dexamethasone—multiple sclerosis	7.87e-05	0.000912	CcSEcCtD
Bosutinib—Pain—Betamethasone—multiple sclerosis	7.8e-05	0.000904	CcSEcCtD
Bosutinib—Pain—Dexamethasone—multiple sclerosis	7.8e-05	0.000904	CcSEcCtD
Bosutinib—Nervous system disorder—Prednisone—multiple sclerosis	7.79e-05	0.000903	CcSEcCtD
Bosutinib—ABL1—cerebellum—multiple sclerosis	7.73e-05	0.000735	CbGeAlD
Bosutinib—Skin disorder—Prednisone—multiple sclerosis	7.72e-05	0.000895	CcSEcCtD
Bosutinib—Gefitinib—ALB—multiple sclerosis	7.7e-05	0.487	CrCbGaD
Bosutinib—Ill-defined disorder—Methotrexate—multiple sclerosis	7.55e-05	0.000875	CcSEcCtD
Bosutinib—Anaemia—Methotrexate—multiple sclerosis	7.52e-05	0.000872	CcSEcCtD
Bosutinib—Feeling abnormal—Dexamethasone—multiple sclerosis	7.52e-05	0.000872	CcSEcCtD
Bosutinib—Feeling abnormal—Betamethasone—multiple sclerosis	7.52e-05	0.000872	CcSEcCtD
Bosutinib—Gastrointestinal pain—Betamethasone—multiple sclerosis	7.46e-05	0.000865	CcSEcCtD
Bosutinib—Gastrointestinal pain—Dexamethasone—multiple sclerosis	7.46e-05	0.000865	CcSEcCtD
Bosutinib—Malaise—Methotrexate—multiple sclerosis	7.34e-05	0.000851	CcSEcCtD
Bosutinib—Leukopenia—Methotrexate—multiple sclerosis	7.28e-05	0.000844	CcSEcCtD
Bosutinib—Urticaria—Dexamethasone—multiple sclerosis	7.25e-05	0.00084	CcSEcCtD
Bosutinib—Urticaria—Betamethasone—multiple sclerosis	7.25e-05	0.00084	CcSEcCtD
Bosutinib—Musculoskeletal discomfort—Prednisone—multiple sclerosis	7.24e-05	0.000839	CcSEcCtD
Bosutinib—Dizziness—Prednisolone—multiple sclerosis	7.23e-05	0.000838	CcSEcCtD
Bosutinib—Asthenia—Triamcinolone—multiple sclerosis	7.22e-05	0.000836	CcSEcCtD
Bosutinib—Abdominal pain—Betamethasone—multiple sclerosis	7.21e-05	0.000836	CcSEcCtD
Bosutinib—Body temperature increased—Dexamethasone—multiple sclerosis	7.21e-05	0.000836	CcSEcCtD
Bosutinib—Body temperature increased—Betamethasone—multiple sclerosis	7.21e-05	0.000836	CcSEcCtD
Bosutinib—Abdominal pain—Dexamethasone—multiple sclerosis	7.21e-05	0.000836	CcSEcCtD
Bosutinib—Asthenia—Methylprednisolone—multiple sclerosis	7.2e-05	0.000834	CcSEcCtD
Bosutinib—Pruritus—Triamcinolone—multiple sclerosis	7.11e-05	0.000825	CcSEcCtD
Bosutinib—Cough—Methotrexate—multiple sclerosis	7.1e-05	0.000823	CcSEcCtD
Bosutinib—Pruritus—Methylprednisolone—multiple sclerosis	7.1e-05	0.000823	CcSEcCtD
Bosutinib—CSNK1E—Betamethasone—Methylprednisolone—multiple sclerosis	7.07e-05	0.0275	CbGdCrCtD
Bosutinib—CSNK1E—Dexamethasone—Methylprednisolone—multiple sclerosis	7.07e-05	0.0275	CbGdCrCtD
Bosutinib—PDGFRB—brain—multiple sclerosis	7.04e-05	0.00067	CbGeAlD
Bosutinib—CSNK1E—Dexamethasone—Betamethasone—multiple sclerosis	6.96e-05	0.0271	CbGdCrCtD
Bosutinib—CSNK1E—Betamethasone—Dexamethasone—multiple sclerosis	6.96e-05	0.0271	CbGdCrCtD
Bosutinib—Arthralgia—Methotrexate—multiple sclerosis	6.93e-05	0.000803	CcSEcCtD
Bosutinib—Chest pain—Methotrexate—multiple sclerosis	6.93e-05	0.000803	CcSEcCtD
Bosutinib—Myalgia—Methotrexate—multiple sclerosis	6.93e-05	0.000803	CcSEcCtD
Bosutinib—Decreased appetite—Prednisone—multiple sclerosis	6.91e-05	0.000801	CcSEcCtD
Bosutinib—Rash—Prednisolone—multiple sclerosis	6.89e-05	0.000799	CcSEcCtD
Bosutinib—Dermatitis—Prednisolone—multiple sclerosis	6.89e-05	0.000798	CcSEcCtD
Bosutinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—multiple sclerosis	6.88e-05	0.000797	CcSEcCtD
Bosutinib—Diarrhoea—Methylprednisolone—multiple sclerosis	6.87e-05	0.000796	CcSEcCtD
Bosutinib—Fatigue—Prednisone—multiple sclerosis	6.85e-05	0.000794	CcSEcCtD
Bosutinib—Headache—Prednisolone—multiple sclerosis	6.85e-05	0.000794	CcSEcCtD
Bosutinib—Discomfort—Methotrexate—multiple sclerosis	6.84e-05	0.000793	CcSEcCtD
Bosutinib—CSNK1E—Betamethasone—Triamcinolone—multiple sclerosis	6.8e-05	0.0264	CbGdCrCtD
Bosutinib—CSNK1E—Dexamethasone—Triamcinolone—multiple sclerosis	6.8e-05	0.0264	CbGdCrCtD
Bosutinib—Dizziness—Triamcinolone—multiple sclerosis	6.65e-05	0.000771	CcSEcCtD
Bosutinib—Anaphylactic shock—Methotrexate—multiple sclerosis	6.64e-05	0.00077	CcSEcCtD
Bosutinib—Dizziness—Methylprednisolone—multiple sclerosis	6.64e-05	0.000769	CcSEcCtD
Bosutinib—Infection—Methotrexate—multiple sclerosis	6.6e-05	0.000765	CcSEcCtD
Bosutinib—Feeling abnormal—Prednisone—multiple sclerosis	6.55e-05	0.000759	CcSEcCtD
Bosutinib—Asthenia—Betamethasone—multiple sclerosis	6.55e-05	0.000759	CcSEcCtD
Bosutinib—Asthenia—Dexamethasone—multiple sclerosis	6.55e-05	0.000759	CcSEcCtD
Bosutinib—Nervous system disorder—Methotrexate—multiple sclerosis	6.51e-05	0.000755	CcSEcCtD
Bosutinib—Thrombocytopenia—Methotrexate—multiple sclerosis	6.5e-05	0.000754	CcSEcCtD
Bosutinib—Gastrointestinal pain—Prednisone—multiple sclerosis	6.5e-05	0.000753	CcSEcCtD
Bosutinib—Nausea—Prednisolone—multiple sclerosis	6.5e-05	0.000753	CcSEcCtD
Bosutinib—Pruritus—Betamethasone—multiple sclerosis	6.46e-05	0.000748	CcSEcCtD
Bosutinib—Pruritus—Dexamethasone—multiple sclerosis	6.46e-05	0.000748	CcSEcCtD
Bosutinib—CSNK1E—Betamethasone—Prednisone—multiple sclerosis	6.45e-05	0.0251	CbGdCrCtD
Bosutinib—CSNK1E—Dexamethasone—Prednisone—multiple sclerosis	6.45e-05	0.0251	CbGdCrCtD
Bosutinib—Skin disorder—Methotrexate—multiple sclerosis	6.45e-05	0.000748	CcSEcCtD
Bosutinib—Vomiting—Triamcinolone—multiple sclerosis	6.39e-05	0.000741	CcSEcCtD
Bosutinib—Vomiting—Methylprednisolone—multiple sclerosis	6.38e-05	0.000739	CcSEcCtD
Bosutinib—Rash—Triamcinolone—multiple sclerosis	6.34e-05	0.000735	CcSEcCtD
Bosutinib—Dermatitis—Triamcinolone—multiple sclerosis	6.33e-05	0.000734	CcSEcCtD
Bosutinib—Rash—Methylprednisolone—multiple sclerosis	6.33e-05	0.000733	CcSEcCtD
Bosutinib—Dermatitis—Methylprednisolone—multiple sclerosis	6.32e-05	0.000733	CcSEcCtD
Bosutinib—Urticaria—Prednisone—multiple sclerosis	6.31e-05	0.000732	CcSEcCtD
Bosutinib—Headache—Triamcinolone—multiple sclerosis	6.3e-05	0.00073	CcSEcCtD
Bosutinib—CSNK1E—Betamethasone—Prednisolone—multiple sclerosis	6.3e-05	0.0245	CbGdCrCtD
Bosutinib—CSNK1E—Dexamethasone—Prednisolone—multiple sclerosis	6.3e-05	0.0245	CbGdCrCtD
Bosutinib—Headache—Methylprednisolone—multiple sclerosis	6.29e-05	0.000729	CcSEcCtD
Bosutinib—Body temperature increased—Prednisone—multiple sclerosis	6.28e-05	0.000728	CcSEcCtD
Bosutinib—Abdominal pain—Prednisone—multiple sclerosis	6.28e-05	0.000728	CcSEcCtD
Bosutinib—ABL1—brain—multiple sclerosis	6.28e-05	0.000597	CbGeAlD
Bosutinib—Diarrhoea—Dexamethasone—multiple sclerosis	6.24e-05	0.000724	CcSEcCtD
Bosutinib—Diarrhoea—Betamethasone—multiple sclerosis	6.24e-05	0.000724	CcSEcCtD
Bosutinib—Musculoskeletal discomfort—Methotrexate—multiple sclerosis	6.05e-05	0.000701	CcSEcCtD
Bosutinib—Dizziness—Dexamethasone—multiple sclerosis	6.03e-05	0.000699	CcSEcCtD
Bosutinib—Dizziness—Betamethasone—multiple sclerosis	6.03e-05	0.000699	CcSEcCtD
Bosutinib—Nausea—Triamcinolone—multiple sclerosis	5.97e-05	0.000692	CcSEcCtD
Bosutinib—Nausea—Methylprednisolone—multiple sclerosis	5.96e-05	0.000691	CcSEcCtD
Bosutinib—Dyspnoea—Methotrexate—multiple sclerosis	5.92e-05	0.000686	CcSEcCtD
Bosutinib—Vomiting—Dexamethasone—multiple sclerosis	5.8e-05	0.000672	CcSEcCtD
Bosutinib—Vomiting—Betamethasone—multiple sclerosis	5.8e-05	0.000672	CcSEcCtD
Bosutinib—Decreased appetite—Methotrexate—multiple sclerosis	5.77e-05	0.000669	CcSEcCtD
Bosutinib—Rash—Dexamethasone—multiple sclerosis	5.75e-05	0.000667	CcSEcCtD
Bosutinib—Rash—Betamethasone—multiple sclerosis	5.75e-05	0.000667	CcSEcCtD
Bosutinib—Dermatitis—Dexamethasone—multiple sclerosis	5.75e-05	0.000666	CcSEcCtD
Bosutinib—Dermatitis—Betamethasone—multiple sclerosis	5.75e-05	0.000666	CcSEcCtD
Bosutinib—Gastrointestinal disorder—Methotrexate—multiple sclerosis	5.73e-05	0.000665	CcSEcCtD
Bosutinib—Fatigue—Methotrexate—multiple sclerosis	5.73e-05	0.000664	CcSEcCtD
Bosutinib—Headache—Dexamethasone—multiple sclerosis	5.72e-05	0.000663	CcSEcCtD
Bosutinib—Headache—Betamethasone—multiple sclerosis	5.72e-05	0.000663	CcSEcCtD
Bosutinib—Asthenia—Prednisone—multiple sclerosis	5.7e-05	0.000661	CcSEcCtD
Bosutinib—Pain—Methotrexate—multiple sclerosis	5.68e-05	0.000658	CcSEcCtD
Bosutinib—Pruritus—Prednisone—multiple sclerosis	5.62e-05	0.000652	CcSEcCtD
Bosutinib—Feeling abnormal—Methotrexate—multiple sclerosis	5.47e-05	0.000634	CcSEcCtD
Bosutinib—Diarrhoea—Prednisone—multiple sclerosis	5.44e-05	0.00063	CcSEcCtD
Bosutinib—Gastrointestinal pain—Methotrexate—multiple sclerosis	5.43e-05	0.000629	CcSEcCtD
Bosutinib—Nausea—Dexamethasone—multiple sclerosis	5.42e-05	0.000628	CcSEcCtD
Bosutinib—Nausea—Betamethasone—multiple sclerosis	5.42e-05	0.000628	CcSEcCtD
Bosutinib—Urticaria—Methotrexate—multiple sclerosis	5.28e-05	0.000611	CcSEcCtD
Bosutinib—Dizziness—Prednisone—multiple sclerosis	5.25e-05	0.000609	CcSEcCtD
Bosutinib—Abdominal pain—Methotrexate—multiple sclerosis	5.25e-05	0.000608	CcSEcCtD
Bosutinib—Body temperature increased—Methotrexate—multiple sclerosis	5.25e-05	0.000608	CcSEcCtD
Bosutinib—CHEK2—Danazol—Prednisone—multiple sclerosis	5.17e-05	0.0201	CbGdCrCtD
Bosutinib—Vomiting—Prednisone—multiple sclerosis	5.05e-05	0.000586	CcSEcCtD
Bosutinib—Rash—Prednisone—multiple sclerosis	5.01e-05	0.000581	CcSEcCtD
Bosutinib—Dermatitis—Prednisone—multiple sclerosis	5.01e-05	0.00058	CcSEcCtD
Bosutinib—Headache—Prednisone—multiple sclerosis	4.98e-05	0.000577	CcSEcCtD
Bosutinib—Asthenia—Methotrexate—multiple sclerosis	4.76e-05	0.000552	CcSEcCtD
Bosutinib—Nausea—Prednisone—multiple sclerosis	4.72e-05	0.000547	CcSEcCtD
Bosutinib—ABCB1—retina—multiple sclerosis	4.7e-05	0.000447	CbGeAlD
Bosutinib—Pruritus—Methotrexate—multiple sclerosis	4.7e-05	0.000545	CcSEcCtD
Bosutinib—Diarrhoea—Methotrexate—multiple sclerosis	4.54e-05	0.000527	CcSEcCtD
Bosutinib—Dizziness—Methotrexate—multiple sclerosis	4.39e-05	0.000509	CcSEcCtD
Bosutinib—Vomiting—Methotrexate—multiple sclerosis	4.22e-05	0.000489	CcSEcCtD
Bosutinib—Rash—Methotrexate—multiple sclerosis	4.19e-05	0.000485	CcSEcCtD
Bosutinib—Dermatitis—Methotrexate—multiple sclerosis	4.18e-05	0.000485	CcSEcCtD
Bosutinib—Headache—Methotrexate—multiple sclerosis	4.16e-05	0.000482	CcSEcCtD
Bosutinib—Nausea—Methotrexate—multiple sclerosis	3.94e-05	0.000457	CcSEcCtD
Bosutinib—CYP3A4—nervous system—multiple sclerosis	3.61e-05	0.000343	CbGeAlD
Bosutinib—CYP3A4—central nervous system—multiple sclerosis	3.47e-05	0.00033	CbGeAlD
Bosutinib—ABCB1—medulla oblongata—multiple sclerosis	3.4e-05	0.000323	CbGeAlD
Bosutinib—ABCB1—midbrain—multiple sclerosis	3.11e-05	0.000296	CbGeAlD
Bosutinib—ABCB1—spinal cord—multiple sclerosis	3.03e-05	0.000288	CbGeAlD
Bosutinib—ABCB1—nervous system—multiple sclerosis	2.55e-05	0.000243	CbGeAlD
Bosutinib—ABCB1—central nervous system—multiple sclerosis	2.46e-05	0.000234	CbGeAlD
Bosutinib—ABCB1—cerebellum—multiple sclerosis	2.4e-05	0.000229	CbGeAlD
Bosutinib—ABCB1—brain—multiple sclerosis	1.95e-05	0.000186	CbGeAlD
Bosutinib—FYN—Signaling Pathways—CD80—multiple sclerosis	1.05e-06	6.08e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—IL2RA—multiple sclerosis	1.05e-06	6.07e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—CD80—multiple sclerosis	1.05e-06	6.05e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—CCL5—multiple sclerosis	1.05e-06	6.05e-06	CbGpPWpGaD
Bosutinib—ERBB3—Immune System—IL6—multiple sclerosis	1.04e-06	6.03e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—CCL2—multiple sclerosis	1.04e-06	6.01e-06	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—STAT3—multiple sclerosis	1.04e-06	6.01e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—POMC—multiple sclerosis	1.04e-06	6e-06	CbGpPWpGaD
Bosutinib—LCK—Immune System—CD4—multiple sclerosis	1.03e-06	5.98e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Immune System—STAT3—multiple sclerosis	1.02e-06	5.91e-06	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—IL2—multiple sclerosis	1.02e-06	5.9e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling by GPCR—MAPK1—multiple sclerosis	1.02e-06	5.88e-06	CbGpPWpGaD
Bosutinib—ERBB4—Signaling Pathways—MYC—multiple sclerosis	1.02e-06	5.88e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—POMC—multiple sclerosis	1.02e-06	5.87e-06	CbGpPWpGaD
Bosutinib—ABCB1—Transmembrane transport of small molecules—ALB—multiple sclerosis	1.01e-06	5.87e-06	CbGpPWpGaD
Bosutinib—ERBB4—Signaling Pathways—TGFB1—multiple sclerosis	1.01e-06	5.87e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—CCL2—multiple sclerosis	1.01e-06	5.87e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—TYK2—multiple sclerosis	1.01e-06	5.86e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—BCHE—multiple sclerosis	1.01e-06	5.83e-06	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—IL2—multiple sclerosis	1.01e-06	5.82e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—APOE—multiple sclerosis	1.01e-06	5.81e-06	CbGpPWpGaD
Bosutinib—PTK2B—Signaling Pathways—MYC—multiple sclerosis	1e-06	5.8e-06	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—STAT3—multiple sclerosis	1e-06	5.79e-06	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—STAT3—multiple sclerosis	1e-06	5.79e-06	CbGpPWpGaD
Bosutinib—PTK2B—Signaling Pathways—TGFB1—multiple sclerosis	1e-06	5.78e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—POMC—multiple sclerosis	9.99e-07	5.78e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Immune System—STAT3—multiple sclerosis	9.98e-07	5.77e-06	CbGpPWpGaD
Bosutinib—EGFR—Innate Immune System—IL6—multiple sclerosis	9.96e-07	5.76e-06	CbGpPWpGaD
Bosutinib—ERBB4—Signaling Pathways—MAPK1—multiple sclerosis	9.95e-07	5.76e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—POMC—multiple sclerosis	9.94e-07	5.75e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—CCL2—multiple sclerosis	9.93e-07	5.75e-06	CbGpPWpGaD
Bosutinib—EGFR—Immune System—IL1B—multiple sclerosis	9.91e-07	5.73e-06	CbGpPWpGaD
Bosutinib—EGFR—Disease—CD4—multiple sclerosis	9.91e-07	5.73e-06	CbGpPWpGaD
Bosutinib—EGFR—Immune System—IL2—multiple sclerosis	9.87e-07	5.71e-06	CbGpPWpGaD
Bosutinib—PTK2B—Signaling Pathways—MAPK1—multiple sclerosis	9.81e-07	5.67e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—CCL2—multiple sclerosis	9.78e-07	5.66e-06	CbGpPWpGaD
Bosutinib—LYN—Immune System—STAT3—multiple sclerosis	9.77e-07	5.65e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—CCL2—multiple sclerosis	9.73e-07	5.63e-06	CbGpPWpGaD
Bosutinib—ABL1—Immune System—STAT3—multiple sclerosis	9.72e-07	5.62e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—SPP1—multiple sclerosis	9.69e-07	5.6e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—APOE—multiple sclerosis	9.69e-07	5.6e-06	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—MMP9—multiple sclerosis	9.66e-07	5.59e-06	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—MYC—multiple sclerosis	9.65e-07	5.58e-06	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—STAT3—multiple sclerosis	9.65e-07	5.58e-06	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—TGFB1—multiple sclerosis	9.63e-07	5.57e-06	CbGpPWpGaD
Bosutinib—SRC—Developmental Biology—IL6—multiple sclerosis	9.63e-07	5.57e-06	CbGpPWpGaD
Bosutinib—ERBB3—Disease—IL6—multiple sclerosis	9.62e-07	5.57e-06	CbGpPWpGaD
Bosutinib—FYN—Immune System—STAT3—multiple sclerosis	9.62e-07	5.56e-06	CbGpPWpGaD
Bosutinib—LCK—Innate Immune System—IL6—multiple sclerosis	9.6e-07	5.55e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—STAT3—multiple sclerosis	9.57e-07	5.53e-06	CbGpPWpGaD
Bosutinib—LCK—Immune System—IL1B—multiple sclerosis	9.55e-07	5.52e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—CD4—multiple sclerosis	9.55e-07	5.52e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—IL2—multiple sclerosis	9.55e-07	5.52e-06	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—MMP9—multiple sclerosis	9.53e-07	5.51e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling by GPCR—MAPK1—multiple sclerosis	9.52e-07	5.5e-06	CbGpPWpGaD
Bosutinib—LCK—Immune System—IL2—multiple sclerosis	9.51e-07	5.5e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—IFNG—multiple sclerosis	9.48e-07	5.48e-06	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—MAPK1—multiple sclerosis	9.45e-07	5.46e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—TYK2—multiple sclerosis	9.44e-07	5.46e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Disease—STAT3—multiple sclerosis	9.44e-07	5.46e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—CCR5—multiple sclerosis	9.43e-07	5.45e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—TYK2—multiple sclerosis	9.35e-07	5.41e-06	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—MYC—multiple sclerosis	9.3e-07	5.38e-06	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—MYC—multiple sclerosis	9.3e-07	5.38e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Immune System—MAPK1—multiple sclerosis	9.29e-07	5.38e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—IL2RA—multiple sclerosis	9.29e-07	5.37e-06	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—TGFB1—multiple sclerosis	9.28e-07	5.37e-06	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—TGFB1—multiple sclerosis	9.28e-07	5.37e-06	CbGpPWpGaD
Bosutinib—PTK2—Immune System—IL6—multiple sclerosis	9.28e-07	5.37e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—TYK2—multiple sclerosis	9.21e-07	5.33e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—STAT3—multiple sclerosis	9.21e-07	5.33e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—CD4—multiple sclerosis	9.16e-07	5.3e-06	CbGpPWpGaD
Bosutinib—YES1—Immune System—IL6—multiple sclerosis	9.15e-07	5.29e-06	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—MAPK1—multiple sclerosis	9.1e-07	5.26e-06	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—MAPK1—multiple sclerosis	9.1e-07	5.26e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—CD80—multiple sclerosis	9.09e-07	5.26e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Immune System—MAPK1—multiple sclerosis	9.07e-07	5.25e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—MMP9—multiple sclerosis	9.04e-07	5.23e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—TYK2—multiple sclerosis	9.02e-07	5.22e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—IL2—multiple sclerosis	8.99e-07	5.2e-06	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—MYC—multiple sclerosis	8.97e-07	5.19e-06	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—TGFB1—multiple sclerosis	8.94e-07	5.17e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—TYK2—multiple sclerosis	8.88e-07	5.14e-06	CbGpPWpGaD
Bosutinib—LYN—Immune System—MAPK1—multiple sclerosis	8.88e-07	5.14e-06	CbGpPWpGaD
Bosutinib—FYN—Disease—STAT3—multiple sclerosis	8.88e-07	5.14e-06	CbGpPWpGaD
Bosutinib—CSNK1E—Signaling Pathways—IL6—multiple sclerosis	8.85e-07	5.12e-06	CbGpPWpGaD
Bosutinib—ABL1—Immune System—MAPK1—multiple sclerosis	8.84e-07	5.11e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—TYK2—multiple sclerosis	8.83e-07	5.11e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—STAT3—multiple sclerosis	8.83e-07	5.11e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Disease—MYC—multiple sclerosis	8.77e-07	5.07e-06	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—MAPK1—multiple sclerosis	8.77e-07	5.07e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—CD80—multiple sclerosis	8.76e-07	5.07e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Disease—TGFB1—multiple sclerosis	8.75e-07	5.06e-06	CbGpPWpGaD
Bosutinib—FYN—Immune System—MAPK1—multiple sclerosis	8.74e-07	5.06e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—MAPK1—multiple sclerosis	8.7e-07	5.03e-06	CbGpPWpGaD
Bosutinib—IRAK1—Immune System—IL6—multiple sclerosis	8.68e-07	5.02e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—POMC—multiple sclerosis	8.63e-07	4.99e-06	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—STAT3—multiple sclerosis	8.59e-07	4.97e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Disease—MAPK1—multiple sclerosis	8.58e-07	4.96e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—APOE—multiple sclerosis	8.58e-07	4.96e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—MYC—multiple sclerosis	8.56e-07	4.95e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—TGFB1—multiple sclerosis	8.54e-07	4.94e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—MMP9—multiple sclerosis	8.51e-07	4.92e-06	CbGpPWpGaD
Bosutinib—SRC—Innate Immune System—IL6—multiple sclerosis	8.5e-07	4.92e-06	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—STAT3—multiple sclerosis	8.47e-07	4.9e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—IL1B—multiple sclerosis	8.46e-07	4.89e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—CD4—multiple sclerosis	8.45e-07	4.89e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—CCL2—multiple sclerosis	8.45e-07	4.89e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—IL2—multiple sclerosis	8.42e-07	4.87e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—MAPK1—multiple sclerosis	8.37e-07	4.84e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—POMC—multiple sclerosis	8.32e-07	4.81e-06	CbGpPWpGaD
Bosutinib—EGFR—Immune System—STAT3—multiple sclerosis	8.31e-07	4.81e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling by GPCR—MAPK1—multiple sclerosis	8.27e-07	4.78e-06	CbGpPWpGaD
Bosutinib—FYN—Disease—MYC—multiple sclerosis	8.25e-07	4.77e-06	CbGpPWpGaD
Bosutinib—FYN—Disease—TGFB1—multiple sclerosis	8.23e-07	4.76e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—MYC—multiple sclerosis	8.21e-07	4.75e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—TGFB1—multiple sclerosis	8.19e-07	4.74e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Immune System—IL6—multiple sclerosis	8.17e-07	4.73e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—CCL2—multiple sclerosis	8.14e-07	4.71e-06	CbGpPWpGaD
Bosutinib—FYN—Disease—MAPK1—multiple sclerosis	8.07e-07	4.67e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—STAT3—multiple sclerosis	8.03e-07	4.65e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—MAPK1—multiple sclerosis	8.03e-07	4.64e-06	CbGpPWpGaD
Bosutinib—LCK—Immune System—STAT3—multiple sclerosis	8.01e-07	4.63e-06	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—MYC—multiple sclerosis	7.98e-07	4.62e-06	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—TGFB1—multiple sclerosis	7.96e-07	4.61e-06	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—MYC—multiple sclerosis	7.87e-07	4.55e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—IL2—multiple sclerosis	7.86e-07	4.54e-06	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—TGFB1—multiple sclerosis	7.85e-07	4.54e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling by GPCR—IL6—multiple sclerosis	7.82e-07	4.52e-06	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—MAPK1—multiple sclerosis	7.81e-07	4.52e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—CD80—multiple sclerosis	7.75e-07	4.48e-06	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—MAPK1—multiple sclerosis	7.7e-07	4.45e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—TYK2—multiple sclerosis	7.67e-07	4.44e-06	CbGpPWpGaD
Bosutinib—EGFR—Disease—STAT3—multiple sclerosis	7.67e-07	4.44e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—IL2—multiple sclerosis	7.67e-07	4.43e-06	CbGpPWpGaD
Bosutinib—ERBB4—Signaling Pathways—IL6—multiple sclerosis	7.65e-07	4.42e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—STAT3—multiple sclerosis	7.56e-07	4.38e-06	CbGpPWpGaD
Bosutinib—EGFR—Immune System—MAPK1—multiple sclerosis	7.55e-07	4.37e-06	CbGpPWpGaD
Bosutinib—PTK2B—Signaling Pathways—IL6—multiple sclerosis	7.53e-07	4.36e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—IL2—multiple sclerosis	7.51e-07	4.34e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—MYC—multiple sclerosis	7.46e-07	4.32e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—TGFB1—multiple sclerosis	7.45e-07	4.31e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—MMP9—multiple sclerosis	7.43e-07	4.3e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—TYK2—multiple sclerosis	7.39e-07	4.28e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—STAT3—multiple sclerosis	7.39e-07	4.28e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—IL2—multiple sclerosis	7.39e-07	4.27e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—POMC—multiple sclerosis	7.37e-07	4.26e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—IL2—multiple sclerosis	7.35e-07	4.25e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling by GPCR—IL6—multiple sclerosis	7.31e-07	4.23e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—MAPK1—multiple sclerosis	7.3e-07	4.22e-06	CbGpPWpGaD
Bosutinib—LCK—Immune System—MAPK1—multiple sclerosis	7.28e-07	4.21e-06	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—IL6—multiple sclerosis	7.26e-07	4.2e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—MMP9—multiple sclerosis	7.26e-07	4.2e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—CCL2—multiple sclerosis	7.21e-07	4.17e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Immune System—IL6—multiple sclerosis	7.14e-07	4.13e-06	CbGpPWpGaD
Bosutinib—EGFR—Disease—MYC—multiple sclerosis	7.13e-07	4.12e-06	CbGpPWpGaD
Bosutinib—EGFR—Disease—TGFB1—multiple sclerosis	7.11e-07	4.11e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—MMP9—multiple sclerosis	7.1e-07	4.11e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—STAT3—multiple sclerosis	7.09e-07	4.1e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—MYC—multiple sclerosis	7.03e-07	4.07e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—TGFB1—multiple sclerosis	7.01e-07	4.06e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—MMP9—multiple sclerosis	6.99e-07	4.05e-06	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—IL6—multiple sclerosis	6.99e-07	4.04e-06	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—IL6—multiple sclerosis	6.99e-07	4.04e-06	CbGpPWpGaD
Bosutinib—EGFR—Disease—MAPK1—multiple sclerosis	6.97e-07	4.03e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Immune System—IL6—multiple sclerosis	6.97e-07	4.03e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—MMP9—multiple sclerosis	6.96e-07	4.02e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—MAPK1—multiple sclerosis	6.88e-07	3.98e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—MYC—multiple sclerosis	6.87e-07	3.97e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—TGFB1—multiple sclerosis	6.85e-07	3.96e-06	CbGpPWpGaD
Bosutinib—LYN—Immune System—IL6—multiple sclerosis	6.82e-07	3.95e-06	CbGpPWpGaD
Bosutinib—ABL1—Immune System—IL6—multiple sclerosis	6.79e-07	3.93e-06	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—IL6—multiple sclerosis	6.74e-07	3.9e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—MAPK1—multiple sclerosis	6.72e-07	3.89e-06	CbGpPWpGaD
Bosutinib—FYN—Immune System—IL6—multiple sclerosis	6.72e-07	3.89e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—IL6—multiple sclerosis	6.68e-07	3.86e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—STAT3—multiple sclerosis	6.61e-07	3.82e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Disease—IL6—multiple sclerosis	6.59e-07	3.81e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—TYK2—multiple sclerosis	6.55e-07	3.79e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—STAT3—multiple sclerosis	6.54e-07	3.79e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—STAT3—multiple sclerosis	6.45e-07	3.73e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—MAPK1—multiple sclerosis	6.44e-07	3.73e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—IL6—multiple sclerosis	6.43e-07	3.72e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—IL2—multiple sclerosis	6.38e-07	3.69e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling by GPCR—IL6—multiple sclerosis	6.35e-07	3.67e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—STAT3—multiple sclerosis	6.32e-07	3.65e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—STAT3—multiple sclerosis	6.22e-07	3.6e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—BCHE—multiple sclerosis	6.21e-07	3.59e-06	CbGpPWpGaD
Bosutinib—FYN—Disease—IL6—multiple sclerosis	6.2e-07	3.59e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—STAT3—multiple sclerosis	6.18e-07	3.58e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—IL6—multiple sclerosis	6.17e-07	3.57e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—IL2—multiple sclerosis	6.15e-07	3.56e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—MYC—multiple sclerosis	6.14e-07	3.55e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—TGFB1—multiple sclerosis	6.13e-07	3.54e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—MYC—multiple sclerosis	6.08e-07	3.52e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—APOE—multiple sclerosis	6.07e-07	3.51e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—TGFB1—multiple sclerosis	6.07e-07	3.51e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—MMP9—multiple sclerosis	6.04e-07	3.49e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—MAPK1—multiple sclerosis	6.01e-07	3.48e-06	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—IL6—multiple sclerosis	6e-07	3.47e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—MYC—multiple sclerosis	5.99e-07	3.47e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—TGFB1—multiple sclerosis	5.98e-07	3.46e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—MAPK1—multiple sclerosis	5.95e-07	3.44e-06	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—IL6—multiple sclerosis	5.92e-07	3.42e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—MYC—multiple sclerosis	5.87e-07	3.39e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—MAPK1—multiple sclerosis	5.86e-07	3.39e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—TGFB1—multiple sclerosis	5.85e-07	3.39e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—MMP9—multiple sclerosis	5.82e-07	3.37e-06	CbGpPWpGaD
Bosutinib—EGFR—Immune System—IL6—multiple sclerosis	5.8e-07	3.36e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—MYC—multiple sclerosis	5.78e-07	3.34e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—TGFB1—multiple sclerosis	5.76e-07	3.33e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—MYC—multiple sclerosis	5.75e-07	3.32e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—MAPK1—multiple sclerosis	5.74e-07	3.32e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—TGFB1—multiple sclerosis	5.73e-07	3.32e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—MAPK1—multiple sclerosis	5.65e-07	3.27e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—MAPK1—multiple sclerosis	5.62e-07	3.25e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—IL6—multiple sclerosis	5.61e-07	3.25e-06	CbGpPWpGaD
Bosutinib—LCK—Immune System—IL6—multiple sclerosis	5.59e-07	3.24e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—IL2—multiple sclerosis	5.45e-07	3.15e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—STAT3—multiple sclerosis	5.37e-07	3.11e-06	CbGpPWpGaD
Bosutinib—EGFR—Disease—IL6—multiple sclerosis	5.36e-07	3.1e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—IL6—multiple sclerosis	5.28e-07	3.06e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—POMC—multiple sclerosis	5.21e-07	3.01e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—STAT3—multiple sclerosis	5.18e-07	2.99e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—IL6—multiple sclerosis	5.16e-07	2.99e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—MMP9—multiple sclerosis	5.15e-07	2.98e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—MYC—multiple sclerosis	4.99e-07	2.89e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—TGFB1—multiple sclerosis	4.98e-07	2.88e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—IL6—multiple sclerosis	4.95e-07	2.86e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—MAPK1—multiple sclerosis	4.88e-07	2.82e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—MYC—multiple sclerosis	4.81e-07	2.78e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—TGFB1—multiple sclerosis	4.8e-07	2.78e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—ALB—multiple sclerosis	4.75e-07	2.75e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—MAPK1—multiple sclerosis	4.71e-07	2.72e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—IL6—multiple sclerosis	4.62e-07	2.67e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—STAT3—multiple sclerosis	4.58e-07	2.65e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—IL6—multiple sclerosis	4.57e-07	2.64e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—IL6—multiple sclerosis	4.51e-07	2.61e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—IL6—multiple sclerosis	4.41e-07	2.55e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—IL6—multiple sclerosis	4.34e-07	2.51e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—IL6—multiple sclerosis	4.32e-07	2.5e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—MYC—multiple sclerosis	4.26e-07	2.46e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—TGFB1—multiple sclerosis	4.25e-07	2.46e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—MAPK1—multiple sclerosis	4.17e-07	2.41e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—IL6—multiple sclerosis	3.75e-07	2.17e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—APOE—multiple sclerosis	3.74e-07	2.16e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—IL6—multiple sclerosis	3.62e-07	2.09e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—POMC—multiple sclerosis	3.21e-07	1.86e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—IL6—multiple sclerosis	3.2e-07	1.85e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—ALB—multiple sclerosis	2.93e-07	1.69e-06	CbGpPWpGaD
